Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezoli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Daniel, Davey, Kuchava, Vladimer, Bondarenko, Igor, Ivashchuk, Oleksandr, Reddy, Sreekanth, Jaal, Jana, Kudaba, Iveta, Hart, Lowell, Matitashvili, Amiran, Pritchett, Yili, Morris, Shannon R., Sorrentino, Jessica A., Antal, Joyce M., Goldschmidt, Jerome
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048941/
https://ncbi.nlm.nih.gov/pubmed/33348420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33453
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados